

123. Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. *Diabete Metab* 1991; 17: 209-12
124. Leslie P, Jung RT, Isles TE, et al. Energy expenditure in non-insulin dependent diabetic subjects on metformin or sulphonyl-urea therapy. *Clin Sci* 1987; 73: 41-5
125. Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer [review]. *J Clin Oncol* 1993; 11: 1418-29
126. Goodwin PA, Panzarella T, Boyd NF. Weight gain in women with localized breast cancer – a descriptive study. *Breast Cancer Res Treat* 1988; 11: 59-66
127. Hoskin PJ, Ashley S, Yarnold JR. Weight gain after primary surgery for breast cancer—effect of tamoxifen. *Breast Cancer Res Treat* 1992; 22: 129-32
128. Centonze V, Magrone D, Vino M, et al. Flunarizine in migraine prophylaxis: efficacy and tolerability of 5 mg and 10 mg dose levels. *Cephalalgia* 1990; 10: 17-24
129. Meyboom RHB, Ferrari MD, Dieleman BP. Parkinsonism, tardive dyskinesia, akathisia and depression induced by flunarizine. *Lancet* 1986; II: 282
130. Baldrati A, Albano F, de Carolis P, et al. Essential tremor and flunarizine: description of a case. *Cephalalgia* 1987; 7: 285
131. Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double blind study in the prophylaxis of migraine. *Headache* 1986; 26: 83-5
132. Vilming S, Standnes B, Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double blind investigation. *Cephalalgia* 1985; 5: 17-23
133. Martinez-Mir I, Navarro-Badenes J, Palop V, et al. Weight gain induced by long-term propranolol treatment [letter]. *Ann Pharmacother* 1993; 27: 512
134. Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. *BMJ* 1990; 300: 902-3
135. Landsberg L, Young JB. Sympathoadrenal activity and obesity – physiological rationale for the use of adrenergic thermogenic drugs. *Int J Obes* 1993; 17: S29-S34
136. Lonnqvist F, Thorne A, Nillsell K, et al. A pathogenetic role of visceral fat beta-3-adrenoreceptors in obesity. *J Clin Invest* 1995; 95: 1109-16
137. Jones DJ, Holt SD, Surtees P, et al. A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: results of a prospective study in 55 patients [see comments]. *Ann R Coll Surg Engl* 1990; 72: 296-8

Correspondence and reprints: Dr H. Pijl, Leiden University Hospital, Department of General Internal Medicine, Building 1, C1-R39, PO Box 9600, 2300 RC Leiden, The Netherlands.

Erratum

Vol. 14, No. 4, page 235: In table I, the second line in column 4 should read 'Q (once daily; n = 11)' and the second line in column 5 should read 'B (twice daily; n = 11)'. These errors carry over to the totals columns (columns 8 and 9) where some of the percentages are incorrect. The final 2 columns should read as follows (altered figures are shown in italics):

Total (%)	
Q (n = 40)	B (n = 39)
20 (50)	16 (41)
8 (20)	7 (18)
6 (15)	7 (18)
5 (13)	6 (15)
1 (3)	3 (8)
2 (5)	6 (15)
1 (3)	1 (3)
	1 (3)
1 (3)	
1 (3)	
1 (3)	
3 (8)	1 (3)
1 (3)	
1 (3)	5 (13)
4 (10)	3 (8)
55	56

[Webster J. A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of Lactation. *Drug Saf* 1996 Apr; 14 (4): 228-238]